Naurex to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

EVANSTON, Ill., March 13, 2015 /PRNewswire/ -- Naurex Inc., a biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that Norbert Riedel, Ph.D., president and chief executive officer, will present at the 22^nd Annual Future Leaders in the Biotech Industry Conference, presented by BioCentury. Dr. Riedel's presentation will take place at 11 a.m. EDT on Friday, March 20, at the Millennium Broadway Hotel in New York City.

About Naurex Inc.
Naurex is a clinical stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system. The company has built a platform for discovering drugs that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Naurex achieve this through a novel mechanism that modulates the NMDA receptor – rather than shutting it down – resulting in drugs that are both highly effective and well tolerated. Naurex's lead molecule, GLYX-13, has demonstrated rapid, robust, and sustained efficacy in multiple Phase 2 clinical studies in depression, an area of high unmet need that has seen little innovation in decades. NRX-1074, a next-generation, orally bioavailable drug candidate, is in Phase 2 clinical development in depression. Naurex's platform has yielded a rich pipeline of subtype-selective NMDA receptor modulators with the potential to treat a broad set of psychiatric and neurologic disorders. For more information, visit www.naurex.com

Media Contacts:
Canale Communications
Ian Stone
[email protected]
619-849-5388

Naurex Inc.
Ashish Khanna
Vice President, Corporate Development
[email protected]
847-871-0377

SOURCE Naurex Inc.

Related Links

http://www.naurex.com